Callan Capital LLC Takes $260,000 Position in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Callan Capital LLC acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,180 shares of the medical equipment provider's stock, valued at approximately $260,000.

A number of other institutional investors have also recently made changes to their positions in SNN. Hexagon Capital Partners LLC lifted its stake in Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after acquiring an additional 406 shares during the last quarter. National Bank of Canada FI lifted its stake in Smith & Nephew SNATS by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after acquiring an additional 446 shares during the last quarter. Bessemer Group Inc. lifted its stake in Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 1,701 shares during the last quarter. Hara Capital LLC lifted its stake in Smith & Nephew SNATS by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 1,957 shares during the last quarter. Finally, Opal Wealth Advisors LLC purchased a new position in Smith & Nephew SNATS in the first quarter worth approximately $73,000. Institutional investors and hedge funds own 25.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SNN. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Canaccord Genuity Group boosted their price objective on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research report on Thursday, May 1st. Six investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Stock Down 2.5%

Shares of NYSE:SNN traded down $0.78 during trading on Friday, hitting $30.29. 1,285,641 shares of the company were exchanged, compared to its average volume of 820,027. The stock has a market capitalization of $13.27 billion, a P/E ratio of 14.02, a PEG ratio of 0.93 and a beta of 0.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.89 and a quick ratio of 1.33. Smith & Nephew SNATS, Inc. has a 12-month low of $23.69 and a 12-month high of $31.72. The firm's 50 day moving average price is $29.33 and its 200-day moving average price is $27.46.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.